Search Results
Your search for The ASCO matches 21740 pages
Showing 21351 - 21400MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer
New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...
Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy
Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia
The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....
FDA Grants Priority Review Designation for Dabrafenib/Trametinib Combination in Metastatic Melanoma
GlaxoSmithKline recently announced that the U.S. Food and Drug Administration has granted Priority Review designation to its supplemental New Drug Applications for the combined use of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic ...
FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia
Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...
FDA Approves First Generic Capecitabine to Treat Colorectal and Breast Cancers
The U.S. Food and Drug Administration (FDA) has approved the first generic version of capecitabine (Xeloda), an oral chemotherapy agent used in the treatment of metastatic colorectal cancer and breast cancers. Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150...
FDA Grants Ofatumumab Breakthrough Therapy Designation for Previously Untreated CLL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ofatumumab (Arzerra) in combination with chlorambucil (Leukeran) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for...
Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
ODAC Recommends Accelerated Approval of Pertuzumab for HER2-Positive, Early-Stage Breast Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a pertuzumab (Perjeta) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive, early-stage breast...
Brachytherapy to Treat Cervical Cancer on the Decline in the United States
A study by researchers at Brigham and Women's Hospital found that brachytherapy was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the...
Dana-Farber Mourns the Passing of Jane Carrie Weeks, MD, MSc, National Leader in Outcomes Research
Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Institute, internationally known for building the discipline of outcomes research in oncology and admired by colleagues as an outstanding mentor, died September 10 after a long illness. She was "one of the true intellectual...
ASCO Issues Statement on National Childhood Obesity Awareness Month
Today, as many as 23 million children and teens are obese or overweight, and it is estimated that more than one-third of U.S. adults (more than 72 million people) are obese, according to a statement released by ASCO to help raise awareness of National Childhood Obesity Awareness Month....
Versatile MicroRNAs Block Cancer Blood Supply, Suppress Metastasis
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center reported in Nature Communications. Patients with lung, ovarian, kidney, or...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
FDA Grants Breakthrough Therapy Status to Entinostat for Advanced Breast Cancer
Syndax Pharmaceuticals Inc today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor (ER)-positive breast cancer when added to exemestane in postmenopausal women whose...
FDA Announces Class-Wide Safety Labeling Changes for Long-Acting Opioid Analgesics to Combat Abuse
The U.S. Food and Drug Administration (FDA) today announced class-wide safety labeling changes and new postmarketing study requirements for all extended-release and long-acting opioid analgesics intended to treat pain. “The FDA is invoking its authority to require safety labeling changes and ...
Researchers Uncover Genetic Cause of Childhood Acute Lymphoblastic Leukemia
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery was reported...
Dr. Larry Norton, Honored at 2013 Breast Cancer Symposium, Calls for Return to the ‘Exploration of Concepts’
Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, is the recipient of the 2013 Gianni Bonadonna Breast Cancer Award, which he received at the 2013 Breast Cancer Symposium. The Symposium is sponsored by ASCO, the American Society of Breast Surgeons, the American Society of Radiation...
Majority of Breast Cancer Deaths Occur in Younger, Unscreened Women, Study Finds
A new analysis has found that most deaths from breast cancer occur in younger women who do not receive regular mammograms. Published early online in Cancer, the study indicates that regular screening before age 50 should be encouraged. The use of mammograms to prevent breast cancer deaths has been ...
Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
FDA Approves Nab-Paclitaxel for Late-Stage Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
Swallowing Exercises Preserve Function in Patients Receiving Radiation for Head and Neck Cancer
A study from UCLA's Jonsson Comprehensive Cancer Center (JCCC) has found that patients with head and neck cancer receiving radiation as part of their treatment were less likely to suffer unwanted side effects such as worsening of diet, need for a feeding tube, or narrowing of the throat passage if...
MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women With DCIS
A large retrospective study reported that adding magnetic resonance imaging (MRI) to mammography before or immediately after surgery was not associated with reduced local recurrence or contralateral breast cancer rates among women with ductal carcinoma in situ (DCIS) of the breast who were treated...
Large Study Shows That Radiation Therapy for DCIS May Not Increase Cardiovascular Disease Risk
A large population-based study in the Netherlands found that women who had received radiation therapy to treat ductal carcinoma in situ of the breast (DCIS) have no increased risk of cardiovascular disease compared to the general population of Dutch women, nor compared to DCIS patients treated with ...
Most Women Have an Inaccurate Perception of Their Breast Cancer Risk, Study Reveals
A large-scale survey of women undergoing mammography screening on Long Island, New York, indicates that the majority (90.6%) either underestimate or overestimate their lifetime risk for developing breast cancer. Furthermore, 4 in 10 women surveyed reported they had never discussed their...
New Report Examines Trends in End-of-Life Care for Patients With Advanced Cancer
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project. The findings also show that a significant number of patients were likely to...
Germline Missense Mutations in BTNL2 Increase Susceptibility to Prostate Cancer
A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...
School-Age Drinking Increases Breast Cancer Risk
The more alcohol young women drink before motherhood, the greater their risk of future breast cancer, according to new research from Washington University School of Medicine in St. Louis. Previous studies have looked at breast cancer risk and alcohol consumption later in life or at the effect of...
St. Jude's Study Yields New Strategy Against High-Risk Leukemia
St. Jude Children’s Research Hospital investigators have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing tumor cells. The findings appear in the August 29 edition of ...
Scripps Florida Investigators Detail Critical Role of NOTCH1 Gene in Many Lung Cancer Cases
Investigators from the Florida campus of The Scripps Research Institute have shown that NOTCH1, a well-known cancer-causing gene implicated in a number of malignancies, plays a far more critical role in non–small cell lung cancer (NSCLC) than previously thought. These findings establish the...
ASCO Launches New Site to Seek Feedback From Cancer Community on Clinical Practice Guidelines
ASCO has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners, and patients with an opportunity to provide feedback or submit evidence on individual published guidelines. “Cancer...
Preclinical Study Finds Tumor Suppressor May Actually Fuel Aggressive Acute Myeloid Leukemia
A study published this week in the Journal of Clinical Investigation suggests that blocking the RUNX1 protein normally credited with suppressing leukemia may be a promising therapeutic strategy for acute myeloid leukemia. Transcription Factor RUNX1 Researchers from Cincinnati Children's Hospital...
Genomic Differences Found in Two Types of Cervical Cancer
A study by Alexi Wright, MD, MPH, and colleagues at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston has found that two common subtypes of cervical cancer, adenocarcinoma and squamous cell carcinoma, have distinct molecular profiles. The results suggest that clinical...
African American Women Less Likely to Receive HPV Vaccine Than Whites, Study Finds
African American women are less likely to receive the vaccine for human papillomavirus (HPV), even with access to health care, according to a study by researchers at the University of Pittsburgh School of Medicine. The findings, published today in the Journal of Adolescent Health, suggest a need...
New Screening Strategy May Detect Ovarian Cancer at Early Stages
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy was described in a study published early online this week in Cancer. A clinical trial is ongoing to verify the findings. Karen Lu, MD, of The University of...
Sorafenib Granted Priority Review for Differentiated Thyroid Cancer
Bayer HealthCare and Onyx Pharmaceuticals announced that the FDA has granted priority review designation to the supplemental new drug application of sorafenib (Nexavar) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The...
Task Force Recommends Interventions to Prevent Tobacco Use in Children
The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on primary care interventions to prevent tobacco use in children and adolescents. The Task Force recommends that primary care clinicians provide interventions, including education or brief...
FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma
Ceptaris Therapeutics, Inc, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug mechlorethamine gel (Valchlor) for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who...
Smoking Cessation and Prevention App Free on iTunes
An app to prevent teens from smoking and encourage them to quit if they have started is now available at no cost on the Apple iTunes Store. “Our app combines education and entertainment with comics and interactive games,” said Designer Alexander Prokhorov, MD, PhD, a Professor in the...
Enhanced Treatment, Surveillance Needed for Certain Melanoma Patients to Prevent Secondary Cancers, Researchers Say
Researchers at Moffitt Cancer Center in Tampa, Florida, suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy with other inhibitors, especially as they become...
Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds
A new population-based study has found that patients with glioblastoma who died in 2010, after the FDA approval of bevacizumab (Avastin), had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of brain...
Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic ...
Researchers Identify Key Protein in Treatment-Resistant Prostate Cancer
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African American, and Hispanic men, according to the Centers for Disease Control. However, it remains unclear why, despite treatment, some prostate cancers progress and may become...
New Research Suggests Restricting Calories May Improve Response to Cancer Treatment
New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and efficacy of targeted cancer therapies. Study results were published online...
Best of ASCO 2013: VeriStrat Assay May Help Select NSCLC Patients for Second-Line Therapy
VeriStrat, a serum-based protein assay, can help select which patients with non–small cell lung cancer (NSCLC) who are not known to have epidermal growth factor receptor (EGFR) mutations might benefit from an EGFR-targeted agent, according to a study described at the 2013 Best of ASCO Los...
Multicenter Trial Finds BI-RADS 3 Breast Lesions Have Low Cancer Rate
Based on data from a multisite imaging trial involving more than 2,600 women, researchers say breast lesions categorized as “probably benign” on supplemental screening ultrasound could be reevaluated with imaging in 12 months, reducing patient anxiety, follow-up exams, and unnecessary...
New MRI Technique Reveals Brain Tumor Response to Antiangiogenesis Therapy
A new way of analyzing data acquired in magnetic resonance imaging (MRI) appears to be able to identify whether or not tumors are responding to antiangiogenesis therapy, which may help physicians determine the most appropriate treatments for patients. In a report published online in Nature...
